| vildagliptin / Generic mfg. |
ACTRN12610001104044: Effects of dipeptidyl peptidase IV (DPP-IV) inhibition (vildagliptin) on plasma concentrations of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) during intraduodenal fat infusion. |
|
|
| Not yet recruiting | 4 | 16 | | | Royal Adelaide Hospital, Novartis Pharmaceuticals Australia Pty. Ltd. | Physiological study to investigate the effects of intraduodenal fat in healthy volunteers.
Outcomes may have implications for type 2 diabetes and obesity. | | | | |
ACTRN12612001005842: Does the drug Galvus enhance the effects of a protein preload to reduce blood glucose concentrations after a meal? |
|
|
| Not yet recruiting | 4 | 22 | | | Professor Michael Horowitz, Novartis Pharmaceuticals Australia Pty. Ltd. | Type 2 diabetes | | | | |
ACTRN12613000224729: The efficacy and tolerability of Galvus (Vildagliptin) compared to Sulfonylureas in patients with new onset diabetes after transplantation (NODAT) |
|
|
| Not yet recruiting | 4 | 48 | | | Sydney Local Health District, Novartis Pharmaceuticals Pty Ltd | New onset diabetes after transplant, Renal Transplant | | | | |
ACTRN12613000418774: Effects of Galvus (Vildagliptin) on Markers of Inflammation in Diabetic Foot Ulcer: A prospective, randomized, double-blind, placebo-controlled pilot study |
|
|
| Recruiting | 4 | 50 | | | Assoc. Professor Usman H. Malabu; FRCPI, FRACP., Novartis Pharmaceuticals | Type 2 Diabetes
Diabetic Foot Ulcer, Anti-inflammatory effects of Vildagliptin, Diabetic foot ulcer healing properties of Vildagliptin | | | | |
ACTRN12614001117606: The role of glucagon-like peptide-1 (GLP-1) in glycaemic, triglyceride and energy expenditure responses to fat in type 2 diabetes. |
|
|
| Recruiting | 4 | 20 | | | Dr Tanya Little, Novartis Pharmaceuticals Australia Pty. Ltd. | Type 2 diabetes | | | | |
2008-004231-38: Effects of vildagliptin (Galvus®) on beta-cell function and turnover in humans |
|
|
| Ongoing | 4 | 40 | Europe | Tablet, Galvus | Department of Medicine I, University Hospital St.Josef-Hospital, Ruhr University Bochum | Diabetes mellitus, beta-cell function before and after pancreatic surgery | | | | |
ChiCTR-TRC-12002553: Vildagliptin on glycemic control in newly diagnosed type 2 diabetes in the short-term insulin pump therapy and remission: a prospective, randomized, open, controlled single-center clinical study |
|
|
| Completed | 4 | 60 | | CSII monotherapy ;CSII + Vildagliptin 50mg bid | Department of Endocrinology and Metabolism, Nanfang Hospital, Southern Medical University; Level of the institution：, Hospital | Diabetes | | | | |
2013-002955-13: Effects of vildaglipitin and glimepiride on variability of glycemic values and cardiovascular risk in diabetic patients is not well controlled with insulin evening Effetti del farmaco vildagliptin e glimepiride sulla variabilità della glicemia e sul rischio cardiovascolare in pazienti diabetici non ben controllati con l’insulina serale |
|
|
| Ongoing | 4 | 68 | Europe | Tablet, Galvus, Amaryl | AFAR, AFAR | type 2 diabetes type 2 diabetes in failure with basal insulin, type 2 diabetes not controlled with insulin diabete di tipo 2 non ben controllato con insulina, Diseases [C] - Hormonal diseases [C19] | | | | |
| Ongoing | 4 | 14 | Europe | Chewable tablet, Galvus | KULeuven, KULeuven | healthy volunteers no medical condition, drug will be studied because they are known to influence gastric motility, healthy subjects, Body processes [G] - Digestive System and Oral Physiological Phenomena [G10] | | | | |
ChiCTR-TRC-13003858: The study of Dipeptidyl peptidase-IV inhibitor's efficacy and safety when it is applied on type 2 diabetes whose blood suger was poorly controlled with original oral antidiabetic drug |
|
|
| Completed | 4 | 40 | | saxagliptin vs Vildagliptin | The First Hospital, Guangzhou Medical University; The First Hospital, Guangzhou Medical University, Pharmaceutical Association | Type 2 diabetes mellitus | | | | |
ChiCTR-IPR-15005986: Effects of vildagliptin combined with insulin on the daily acute glucose fluctuations by continuous subcutaneous glucose monitoring in patients with type 1 diabetes compared with conventional insulin therapy |
|
|
| Recruiting | 4 | 44 | | vildagliptin 50mg bid+conventional intensive insulin therepy ;conventional insulin therapy | Shenzhen People's Hospital; Shenzhen People's Hospital, self- financing | type 1 diabetes | | | | |
2007-001049-16: A multi-centre, randomised, double blind, parallel group study to investigate the efficacy and tolerability of treatment (24 weeks double blind phase followed by open-label extension) with either vildagliptin ( Galvus) or placebo combined with metformin in achieving optimal glycaemic control in older patients with type 2 diabetes. |
|
|
| Ongoing | 4 | 438 | Europe | Vildagliptin, LAF237A, | Novartis Pharmaceuticals UK Ltd | Type 2 Diabetes | | | | |
2010-019346-11: Effects of vildagliptin twice daily vs. sitagliptin once daily on reduction of oxidative stress and inflammation by blunting interprandial acute glucose fluctuations in patients with type 2 diabetes - PROBE Design (Multicenter Prospective, Randomized, Open-label parallel group with a blinded-endpoint) Effetti di vildagliptin(50 mg x 2/die) vs sitagliptin (100 mg/die) sullo stress ossidativo e sull\'infiammazione in relazione alle fluttuazioni glicemiche interprandiali in pazienti con diabete mellito tipo 2 - PROBE Design (Multicenter Prospective, Randomized, Open-label parallel group with a blinded-endpoint) |
|
|
| Ongoing | 4 | 90 | Europe | Tablet | AZIENDA OSPEDALIERA UNIVERSITARIA DELLA SECONDA UNIVERSITA\' DEGLI STUDI DI NAPOLI | patients with type 2 diabetes poorly controlled PAZIENTI DIABETICI SCOMPENSATI | | | | |
| Ongoing | 4 | 20 | Europe | Vildagliptin, Galvus | Erasmus Medical Center, Novartis Europharma Ltd. | impaired fasting glucose/impaired glucose tolerance, prediabetes | | | | |
ChiCTR2000040826: A comparative study of acarbose, vildagliptin and saxagliptin intended for better efficacy and safety on type 2 diabetes mellitus treatment |
|
|
| Completed | 4 | 90 | | Acarbose tablets orally (100 mg/tablet, Bayer, Leverkusen, Germany) 3 times each day with 100 mg each time ;vildagliptin tablets orally (50 mg/tablet, AstraZeneca, Cambridge, London, England) 2 times each day with 50 mg each time ;saxagliptin tablets orally (5 mg/tablet, AstraZeneca, Cambridge, London, England) one time each day with 5 mg each time | Affiliated Hospital of Qiingdao University; Affiliated Hospital of Qiingdao University, Self-financing | Type 2 diabetes mellitus | | | | |
ChiCTR-OIN-16009294: A comparative study of vildagliptin and other OAD in patients with T2DM inadequately controlled with current therapy |
|
|
| Not yet recruiting | 4 | 200 | | vildagliptin 50mg qd or 50mg bid ;any OAD | The Second affiliated hospital of Fujian Medical University; The Second affiliated hospital of Fujian Medical University, self-financing | type 2 diabetes | | | | |
2013-004737-33: A prospective, multicenter, randomized, open-label study of 12 week duration to evaluate the effect of VILDagliptin added to insulin on glycaemic control in haemoDIALyzed patients with type 2 diabetes: probe analysis of CGM Etude prospective randomisée multicentrique d’évaluation de la VILDagliptine associée à l’insuline sur le contrôle glycémique chez les patients hémoDIALysés diabétiques de type 2 : étude VILDDIAL |
|
|
| Not yet recruiting | 4 | 70 | Europe | Vildagliptine, Tablet, Solution for injection, Suspension for injection, Galvus, LANTUS 100 unités/ml solution injectable, LANTUS 100 unités/ml solution injectable en cartouche, LANTUS 100 unités/ml solution injectable en cartouche pour OptiClik, Lantus OptiSet 100 unités/ml solution injectable en stylo prérempli, Lantus SoloStar 100 unités/ml solution injectable en stylo prérempli, Levemir 100 U/ml, solution injectable en cartouche, Levemir 100 U/ml, solution injectable en stylo prérempli, Levemir InnoLet 100 U/ml, solution injectable en stylo prérempli, Levemir FlexTouch 100 U/ml, solution injectable en stylo prérempli, Apidra 100 unités/ml solution injectable en flacon, Apidra 100 unités/ml solution injectable en cartouche, Apidra 100 unités/ml solution injectable en cartouche pour OptiClik, Apidra 100 unités/ml solution injectable en stylo prérempli, Apidra SoloStar 100 unités/ml solution injectable en stylo prérempli, Humalog 100 UI/ml, solution injectable en flacon, Humalog 100 UI/ml, solution injectable en cartouche, Humalog Mix25 100 UI/ml suspension injectable en flacon, Humalog Mix25 100 UI/ml suspension injectable en cartouche, Humalog Mix50 100 UI/ml suspension injectable en flacon, Humalog Mix50 100 UI/ml suspension injectable en cartouche, Humalog BASAL 100 UI/ml suspension injectable en cartouche, Humalog Pen 100 UI/ml, solution injectable, Humalog Mix25 100 UI/ml Pen, suspension injectable, Humalog Mix50 100 UI/ml Pen, suspension injectable, Humalog BASAL 100 UI/ml Pen, suspension injectable, Humalog 100 UI/ml KwikPen, solution injectable, Humalog Mix25 100 UI/ml KwikPen, suspension injectable, Humalog Mix50 100 UI/ml KwikPen, suspension injectable, Humalog BASAL 100 UI/ml KwikPen, suspension injectable, NovoRapid 100 U/ml, solution injectable, NovoRapid Penfill 100 U/ml, solution injectable en cartouche, NovoRapid FlexPen 100 U/ml, solution injectable en stylo prérempli, NovoRapid InnoLet 100 U/ml, solution injectable en stylo prérempli, NovoRapid FlexTouch 100 U/ml, solution injectable en stylo prérempli | Hôpitaux Universitaires de Strasbourg, HÔPITAUX UNIVERSITAIRES DE STRASBOURG, NOVARTIS PHARMASAS | haemodialyzed patients with type 2 diabetes patients hémodialysés et présentant un diabète de type 2, haemodialyzed patients with type 2 diabetes patients hémodialysés et présentant un diabète de type 2, Diseases [C] - Nutritional and Metabolic Diseases [C18] | | | | |
NCT04485845: Metformin Versus Vildagliptin in Reducing Risk of Metabolic Syndrome Complications Progression |
|
|
| Recruiting | 4 | 39 | RoW | Vildagliptin, Captopril Tablets, MetFORMIN 500 Mg Oral Tablet | Cairo University | Metabolic Syndrome, Diabete Type 2, Kidney Insufficiency | 08/20 | 09/20 | | |
ChiCTR2000037907: Effects of DPP-4 inhibitors on health-related quality of life in patients with type 2 diabetes |
|
|
| Not yet recruiting | 4 | 600 | | DPP-4 inhibitors (including sitagliptin, sitagliptin, vildagliptin, linagliptin, alogliptin) ;GLP-1 receptor agonists (including exenatide, liraglutide, benaglutide, lixisenatide) ;SGLT-2 inhibitor (including dapagliflozin, empagliflozin, canagliflozin) | Shanghai Minhang Hospital; Shanghai Minhang Hospital, 2019 Shanghai Health Commission Research Project | Type 2 diabetes | | | | |
